Pfizer PE Ratio 2012-2026 | PFE
Current and historical p/e ratio for Pfizer (PFE) from 2012 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Pfizer PE ratio as of September 04, 2026 is 9.33.
| Pfizer PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-09-04 | 28.45 | 37.43 | |
| 2026-06-30 | 23.67 | $0.76 | 31.14 |
| 2026-03-31 | 27.15 | $1.31 | 20.72 |
| 2025-12-31 | 23.68 | $1.36 | 17.41 |
| 2025-09-30 | 23.81 | $1.72 | 13.84 |
| 2025-06-30 | 22.27 | $1.88 | 11.84 |
| 2025-03-31 | 22.84 | $1.38 | 16.55 |
| 2024-12-31 | 23.53 | $1.41 | 16.68 |
| 2024-09-30 | 25.27 | $0.75 | 33.69 |
| 2024-06-30 | 24.09 | $-0.45 | 0.00 |
| 2024-03-31 | 23.54 | $-0.05 | 0.00 |
| 2023-12-31 | 24.06 | $0.37 | 65.02 |
| 2023-09-30 | 27.35 | $1.82 | 15.03 |
| 2023-06-30 | 29.91 | $3.75 | 7.98 |
| 2023-03-31 | 32.92 | $5.07 | 6.49 |
| 2022-12-31 | 40.96 | $5.47 | 7.49 |
| 2022-09-30 | 34.68 | $5.20 | 6.67 |
| 2022-06-30 | 41.24 | $5.11 | 8.07 |
| 2022-03-31 | 40.39 | $4.36 | 9.26 |
| 2021-12-31 | 45.72 | $3.85 | 11.88 |
| 2021-09-30 | 33.01 | $3.41 | 9.68 |
| 2021-06-30 | 29.79 | $2.25 | 13.24 |
| 2021-03-31 | 27.29 | $1.89 | 14.44 |
| 2020-12-31 | 27.43 | $1.63 | 16.83 |
| 2020-09-30 | 25.68 | $1.37 | 18.74 |
| 2020-06-30 | 22.66 | $2.47 | 9.17 |
| 2020-03-31 | 22.40 | $2.74 | 8.17 |
| 2019-12-31 | 26.61 | $2.82 | 9.44 |
| 2019-09-30 | 24.17 | $2.87 | 8.42 |
| 2019-06-30 | 28.87 | $2.20 | 13.12 |
| 2019-03-31 | 28.06 | $1.96 | 14.31 |
| 2018-12-31 | 28.59 | $1.87 | 15.29 |
| 2018-09-30 | 28.64 | $3.96 | 7.23 |
| 2018-06-30 | 23.38 | $3.74 | 6.25 |
| 2018-03-31 | 22.65 | $3.60 | 6.29 |
| 2017-12-31 | 22.90 | $3.52 | 6.51 |
| 2017-09-30 | 22.37 | $1.62 | 13.81 |
| 2017-06-30 | 20.84 | $1.37 | 15.21 |
| 2017-03-31 | 21.02 | $1.19 | 17.67 |
| 2016-12-31 | 19.76 | $1.17 | 16.89 |
| 2016-09-30 | 20.40 | $1.01 | 20.20 |
| 2016-06-30 | 21.03 | $1.13 | 18.61 |
| 2016-03-31 | 17.55 | $1.22 | 14.38 |
| 2015-12-31 | 18.92 | $1.11 | 17.05 |
| 2015-09-30 | 18.26 | $1.33 | 13.73 |
| 2015-06-30 | 19.35 | $1.41 | 13.72 |
| 2015-03-31 | 19.91 | $1.44 | 13.83 |
| 2014-12-31 | 17.67 | $1.42 | 12.44 |
| 2014-09-30 | 16.63 | $1.67 | 9.96 |
| 2014-06-30 | 16.55 | $1.64 | 10.09 |
| 2014-03-31 | 17.75 | $3.17 | 5.60 |
| 2013-12-31 | 16.78 | $3.19 | 5.26 |
| 2013-09-30 | 15.62 | $3.59 | 4.35 |
| 2013-06-30 | 15.11 | $3.63 | 4.16 |
| 2013-03-31 | 15.44 | $2.08 | 7.42 |
| 2012-12-31 | 13.30 | $1.94 | 6.86 |
| 2012-09-30 | 13.06 | $1.28 | 10.20 |
| 2012-06-30 | 11.98 | $1.33 | 9.01 |
| 2012-03-31 | 11.68 | $1.23 | 9.49 |
| 2011-12-31 | 11.04 | $1.27 | 8.70 |
| 2011-09-30 | 8.93 | $1.44 | 6.20 |
| 2011-06-30 | 10.29 | $1.07 | 9.62 |
| 2011-03-31 | 10.05 | $1.05 | 9.57 |
| 2010-12-31 | 8.58 | $1.02 | 8.41 |
| 2010-09-30 | 8.32 | $0.73 | 11.40 |
| 2010-06-30 | 6.84 | $1.05 | 6.51 |
| 2010-03-31 | 8.14 | $1.08 | 7.53 |
| 2009-12-31 | 8.55 | $1.23 | 6.95 |
| 2009-09-30 | 7.70 | $1.21 | 6.37 |
| 2009-06-30 | 6.91 | $1.12 | 6.17 |
| 2009-03-31 | 6.21 | $1.19 | 5.22 |
| 2008-12-31 | 7.90 | $1.20 | 6.58 |
| 2008-09-30 | 8.08 | $1.56 | 5.18 |
| 2008-06-30 | 7.53 | $1.33 | 5.66 |
| 2008-03-31 | 8.88 | $1.10 | 8.08 |
| 2007-12-31 | 9.51 | $1.17 | 8.13 |
| 2007-09-30 | 10.10 | $2.08 | 4.86 |
| 2007-06-30 | 10.45 | $2.43 | 4.30 |
| 2007-03-31 | 10.21 | $2.58 | 3.96 |
| 2006-12-31 | 10.36 | $2.66 | 3.89 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $162.156B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1081.958B | 36.50 |
| Johnson & Johnson (JNJ) | United States | $663.276B | 25.34 |
| AbbVie (ABBV) | United States | $453.112B | 23.59 |
| Merck (MRK) | United States | $370.890B | 46.83 |
| Roche Holding AG (RHHBY) | Switzerland | $350.157B | 0.00 |
| Novartis AG (NVS) | Switzerland | $305.285B | 18.43 |
| Novo Nordisk (NVO) | Denmark | $208.069B | 11.59 |
| Sanofi (SNY) | France | $107.257B | 9.03 |
| Bayer (BAYRY) | Germany | $55.767B | 9.92 |
| Innoviva (INVA) | United States | $1.541B | 5.27 |